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Abstract There is increasing interest in identifying potent
inhibitors of telomerase because the enzyme plays a crucial role
in the development of cellular immortality and carcinogenesis.
We hypothesized that 9-hydroxyellipticine (9-HE), an antitumor
alkaloid, would inhibit telomerase activity because the drug has a
unique mechanism of inhibiting phosphorylation of mutant p53
protein via inhibition of protein kinases, thereby restoring wild-
type p53 function. This study was conducted to examine the
effect of 9-HE on telomerase activity in human pancreatic cancer
cells with differing p53 gene status. 9-HE treatment at relatively
high concentrations resulted in rapid, complete inhibition of
telomerase activity, irrespective of the p53 status. We conclude
that 9-HE may exert a strong inhibitory effect on telomerase
activity possibly through inhibition of protein kinases rather than
through restoration of functional wild-type p53.
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1. Introduction
Telomerase is a ribonucleoprotein enzyme that elongates
and/or maintains telomeric DNA, and it is considered to
play an important role in the development of cellular immor-
tality and carcinogenesis [1,2]. Telomerase has been recog-
nized as a potent diagnostic marker in a variety of human
cancers because of its prevalence in most tumor cells ; the
majority of normal cells adjacent to tumors lack detectable
levels of telomerase activity [3,4]. We reported previously that
telomerase activity was highly elevated in 80% of the speci-
mens from surgically resected lesions of pancreatic carcinoma
[5,6] and in 75% of pancreatic juice samples obtained from
patients with ductal carcinoma [7]. The speci¢c association of
telomerase activity with cancers has led researchers to target
this enzyme for therapeutic application [8]. Several telomerase
inhibitors have been reported, including inhibitors of retrovi-
ral reverse transcriptase [9], peptic nucleic acids [10], hammer-
head ribozymes [11], antisense telomerase RNA component
(hTR) [12], protein kinase C inhibitors [13], cisplatin [14],
and Oxytricha telomere DNA binding proteins [15]. Studies
of the mechanism of telomerase activity inhibition would fa-
cilitate the understanding of the functional role of this enzyme
in tumor cell growth and its interaction with other compo-
nents.
Recent studies have suggested a close linkage between the
p53 tumor suppressor gene and telomerase activity. For in-
stance, activation of telomerase was observed in immortalized
human epithelial cells transfected with a mutant p53 [16] and
in human keratinocytes transduced with human papillomavi-
rus type 16 E6 protein, which mediates degradation of p53
protein [17,18]. These studies suggest that abrogation of p53
leads to activation of telomerase activity, which is normally
downregulated in an indirect manner by the wild-type p53.
Based on these studies, we hypothesized that 9-hydroxyellip-
ticine (9-HE), an ellipticine derivative, would suppress telo-
merase activity because the drug has a unique anticancer
mechanism of inhibiting phosphorylation of mutant p53 pro-
tein via inhibition of protein kinases, thereby restoring wild-
type p53 function [19,20].
In the present study, we investigated the e¡ect of 9-HE on
telomerase activity in cultured human pancreatic cancer cells.
Other chemotherapeutic agents, which act by di¡erent mech-
anisms, were tested for comparison with 9-HE. Our results
demonstrated that of all the drugs tested, 9-HE alone caused
speci¢c inhibition of telomerase activity of treated cells re-
gardless of the p53 gene status, thus implying that inhibition
of protein kinases rather than restoration of wild-type p53
may be involved in the mechanism behind the e¡ect.
2. Materials and methods
2.1. Cell lines
Six human pancreatic cancer cell lines were used in this study: MIA
PaCa-2 (mutant p53) was provided by the Japanese Cancer Resource
Bank (Tokyo, Japan); SUIT-2 (mutant p53), PANC-1 (mutant p53),
KP-1N (mutant p53), AsPC-1 (p53-negative), and KP-3 (wild-type
p53) were generously donated by Dr. H. Iguchi (National Kyushu
Cancer Center, Fukuoka, Japan) [21]. Cells were maintained in Dul-
becco’s modi¢ed Eagle’s medium (DMEM, Sigma Chemical Co., St.
Louis, MO, USA) supplemented with 10% fetal bovine serum, strep-
tomycin (100 Wg/ml), and penicillin (100 U/ml) at 37‡C in a humidi¢ed
atmosphere containing 10% CO2.
2.2. Drug treatment
Exponentially growing cells were plated at a density of 1U105 cells/
well in 24-well plates. After overnight incubation, the cells were con-
tinuously exposed to various concentrations (1^10 WM) of 9-HE,
which was kindly donated by M. Ohashi (Tanabe Seiyaku Co. Ltd.,
Tokyo, Japan). For comparison, MIA PaCa-2 cells were treated with
other chemotherapeutic agents in the same manner: VP-16 (10 WM),
cisplatin (30 WM), mitomycin C (5 WM), 5-£uorouracil (300 WM), and
vincristine (5 WM). The concentrations of these chosen drugs corre-
spond to the concentrations required to achieve 40^50% cell killing,
which is almost equivalent to the killing rate encountered in 9-HE
treatment at a concentration of 10 WM, measured by the cell killing
assay (see below) on day 5 of treatment. Antiproliferative e¡ects were
evaluated daily based on cell number as assessed in a particle distri-
bution analyzer, CDA500 (Sysmex, Kobe, Japan).
2.3. Cell killing assay
Cytotoxicity was evaluated using a multiwell £uorescence scanner
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by the method described by Nieminen et al. [22] with minor modi¢-
cations. This method allows an indirect measurement of cell killing
and is based on the binding of propidium iodide (PI) to the nuclei of
cells whose plasma membranes have become permeable due to cell
death. Brie£y, 10 Wl of a 3.06 mM solution of PI was added to
each well for a ¢nal concentration of 30 WM. After a 60-min incuba-
tion at 37‡C, initial £uorescence unit from each well was measured in
a CYTOFLUOR II (PerSeptive Biosystems Inc., Framingham, MA,
USA) using 530-nm excitation and 645-nm emission ¢lters. After
reading, 20 Wl of 32.54 mM digitonin (600 WM) was added to each
well to permeabilize all cells and label all nuclei with PI. After a 30-
min incubation at 37‡C, £uorescence was measured again to obtain a
value corresponding to 100% cell death. The percentage of dead cells
was calculated as the proportion of a £uorescence unit of dead cells to
that of total cells.
2.4. Telomerase activity assay
Cells were harvested by centrifugation, resuspended in CHAPS lysis
bu¡er (10 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM EGTA,
0.1 mM 4-(2-aminoethyl)-benzenesulfonyl £uoride hydrochloride,
5 mM L-mercaptoethanol, 0.5% CHAPS, 10% glycerol), and incu-
bated for 30 min on ice. After centrifugation at 15 000Ug for 20 min
at 4‡C, the supernatants were transferred to fresh tubes and used as
the cell extracts for telomerase assay. Telomerase activity was meas-
ured by the PCR-based telomeric repeat ampli¢cation protocol
(TRAP) assay [2] with minor modi¢cations. In brief, 2 Wl of the cell
extracts (equivalent to 1000 cells) were incubated in a reaction mixture
containing 50 mM deoxynucleotide triphosphate, 2 units of Taq DNA
polymerase (Promega Corp., Madison, WI, USA), and 0.1 Wg of TS
primer (5P-AATCCGTCGAGCAGAGTT-3P) at 20‡C for 30 min.
After incubation, 0.1 Wg of CX primer (5P-CCCTTACCCTTACCCT-
TACCCTAA-3P) was added, and the reaction mixture was subjected
to a 31-cycle PCR ampli¢cation. The PCR products were resolved by
electrophoresis on a non-denaturing 12% polyacrylamide gel and the
gel was stained with SYBR green DNA stain (FMC BioProducts,
Rockland, ME, USA). Signal intensity of the 6-base ladder was meas-
ured by NIH image, version 1.60 (NTIS, Spring¢eld, VA, USA) and
used for quantitative analysis. The relative density in each treated
sample was expressed as its percentage of untreated control after
subtraction from background.
3. Results
Changes in total cell number of MIA PaCa-2 cells treated
with 9-HE (10 WM), VP-16 (10 WM), cisplatin (30 WM), mito-
mycin C (5 WM), 5-£uorouracil (300 WM), and vincristine
(5 WM) are shown in Fig. 1. Compared with untreated cells
(control), 9-HE treatment completely inhibited cell growth, as
did the other drugs. Using the PCR-based TRAP assay, we
¢rst assessed whether 9-HE inhibits telomerase activity in
MIA PaCa-2 cells in culture. 9-HE signi¢cantly inhibited te-
lomerase activity of treated cells in a concentration-dependent
manner (Fig. 2a). Whereas relatively low concentrations of
9-HE (1, 3 WM) resulted in almost no inhibition, treatment
at the highest concentration, 10 WM, completely inhibited ac-
tivity. Time courses of telomerase activity in MIA PaCa-2
cells upon exposure to 10 WM 9-HE are shown in Fig. 2b.
The inhibition of telomerase activity was detectable as early as
3 h after the beginning of drug exposure. At 12 h after ex-
posure, the telomerase ladders were almost undetectable, in-
dicating complete inhibition. The in vitro direct e¡ect of 9-HE
on telomerase activity was analyzed to test the possibility that
9-HE could inhibit the PCR reaction. When MIA PaCa-2 cell
extracts were exposed to 10 WM 9-HE for 3 h before primer
addition, no telomerase inhibition was observed (data not
shown). Therefore, neither a direct in£uence of 9-HE on te-
lomerase activity in a cell-free system nor an inhibition of
PCR reaction seems to be involved in the decline of the en-
zyme activity observed after drug treatment.
To determine whether the observed inhibition of telomerase
activity by 9-HE is due to drug-induced cell killing, we per-
formed a cell killing assay of MIA PaCa-2 cells treated with
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Fig. 1. The daily changes in total cell number of MIA PaCa-2 cells
treated with 9-HE (10 WM), VP-16 (10 WM), cisplatin (30 WM), mi-
tomycin C (5 WM), 5-£uorouracil (300 WM), or vincristine (5 WM).
Cell numbers shown are mean þ S.D. of three independent wells for
each agent.
Fig. 2. Inhibition of telomerase activity in MIA-PaCa 2 cells treated
with 9-HE. a: Cells treated for 48 h with 9-HE at a concentration
of 0 (control), 1, 3, 5, and 10 WM. b: Cells treated with 9-HE for 0
(control), 3, 6, 12, 24, and 48 h at a concentration of 10 WM. Telo-
merase activity was measured using a PCR-based telomerase assay
as described in Section 2. The relative densities of the telomeric lad-
ders in each treated sample are expressed as a percentage of the un-
treated control after subtraction from background (plotted in bar
graphs).
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9-HE. The percentages of dead cells at 6, 24, 48, 72, and 120 h
after treatment with 10 WM 9-HE were 1.0 þ 0.4, 2.7 þ 0.5,
3.8 þ 0.6, 17.4 þ 3.7, and 42.0 þ 5.0%, respectively. Therefore,
9-HE treatment had little or no e¡ect on the rate of cell death
until 72 h after the start of exposure, at which time the in-
hibition of telomerase activity was already apparent.
When other pancreatic cancer cells (SUIT-2, PANC-1, KP-
1N, AsPC-1, KP-3) with di¡erent p53 gene statuses were
treated with 10 WM 9-HE, they all showed similar inhibitory
e¡ects at 48 h after drug exposure (Fig. 3). Furthermore, in
AsPC-1 (p53-negative) and KP-3 (wild-type p53) cells, the
inhibition of telomerase activity was detectable from 3 h after
drug treatment, which is a similar ¢nding to that encountered
in MIA PaCa-2 (mutant p53) cells (data not shown). These
¢ndings indicate that telomerase inhibition caused by 9-HE is
not related to the p53 status of tumor cells.
To examine the speci¢city of telomerase inhibition by 9-HE,
the e¡ect of other cytotoxic agents was investigated under the
same conditions. In contrast to 9-HE, VP-16, cisplatin, 5-£u-
orouracil, mitomycin C, and vincristine had no inhibitory ef-
fect on telomerase activity of treated cells. In fact, cells treated
with VP-16 and 5-£uorouracil had slightly elevated levels of
telomerase activity than that of control cells (Fig. 4).
4. Discussion
In the present study, we have clearly demonstrated that
9-HE, an ellipticine derivative, signi¢cantly inhibited telomer-
ase activity in a time- and concentration-dependent manner in
human pancreatic cancer cells. In contrast, other chemother-
apeutic agents had no e¡ect on the enzymatic activity of
treated cells. These ¢ndings suggest that the telomerase inhi-
bition caused by 9-HE could contribute to its therapeutic
action, which the other drugs lack. 9-HE has potent anti-
cancer activities in a variety of tumors possibly as a result
of intercalation with DNA and/or inhibition of topoisomerase
II [23^25]. Recently, it has been shown that 9-HE has an
additional anticancer mechanism of inhibiting phosphoryl-
ation of mutant p53 protein via inhibition of protein kinases,
such as cdk2 kinase and DNA-activated kinase, which are
responsible for the phosphorylation of p53 [19,20]. Inhibition
of mutant p53 phosphorylation results in a large amount of
dephosphorylated mutant p53, thereby restoring wild-type
p53 function. In other experiments, we found that a relatively
low concentration (1 WM) of 9-HE was su⁄cient to restore the
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Fig. 3. E¡ect of 9-HE treatment on telomerase activity in six pan-
creatic cancer cell lines with di¡ering p53 statuses. Cells were
treated with 9-HE for 48 h at a concentration of 10 WM and telo-
merase activity was assessed.
Fig. 4. E¡ects of chemotherapeutic agents on telomerase activity in MIA-PaCa 2 cells. Cells were treated with VP-16 (10 WM), cisplatin
(30 WM), mitomycin C (5 WM), 5-£uorouracil (300 WM), and vincristine (5 WM) for 24 and 48 h, and telomerase activity was assessed.
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wild-type p53 function and that this e¡ect was speci¢c for cells
containing mutant p53 (unpublished data). Therefore, we hy-
pothesized that the restoration of wild-type p53 or the accu-
mulation of dephosphorylated mutant p53 contributes to the
decline in telomerase activity observed after treatment with 9-
HE.
Recently, the relation between the p53 tumor suppressor
gene and telomerase activity has received much attention.
One ¢nding suggesting a linkage between p53 and telomerase
activity is that normal human breast epithelial cells trans-
fected with a p53 mutant became immortalized and were re-
activated for telomerase [16]. In addition, primary human
keratinocytes transduced with the human papillomavirus
type 16 E6 gene, which binds to the cellular p53 protein
and promotes its degradation, expressed signi¢cant telomerase
activity [18]. These studies imply that inactivation of p53 leads
to activation of telomerase, which is normally downregulated
in an indirect manner by the wild-type p53. More recently, it
has been reported that human non-small-cell lung cancer cells
(wild-type p53) that were stably transfected with sense wild-
type p53 cDNA showed a signi¢cant reduction in telomerase
activity [26]. These ¢ndings are consistent with our hypothesis
that 9-HE might inhibit telomerase activity via the restoration
of wild-type p53. However, in our present study, telomerase
inhibition was almost undetectable after exposure to 9-HE at
a concentration of 1 WM, which is su⁄cient to restore the
wild-type p53 function in cells harboring p53 mutations. Fur-
thermore, the telomerase inhibition was found not only in
mutant p53 expressing cells but also to a similar extent in
p53-negative (AsPC-1) or wild-type p53 (KP-3) cells, thus
the inhibition was not dependent on p53 status. Restoration
of wild-type p53 could not explain the mechanism of inhibit-
ing telomerase activity, at least in p53-negative or wild-type
p53 expressing cells.
Several reports have described a relation between telomer-
ase activity and protein kinases. For example, the protein
kinase C inhibitors bisindolylmaleimide I and H-7 were found
to inhibit telomerase activity in human nasopharyngeal cancer
cells in culture [13]. This e¡ect on telomerase activity was
speci¢c for PKC inhibitors and was not observed in cells
treated with various other chemotherapeutic agents, which is
consistent with our present results. Furthermore, protein
phosphatase 2A inhibits nuclear telomerase activity in human
breast cancer cells, which implies that telomerase is reversibly
regulated by protein phosphorylation and dephosphorylation
through protein kinases and the protein phosphatase 2A [27].
In the light of these ¢ndings, we assume that inhibition of
protein kinases such as cdk2 kinase and DNA-activated ki-
nase may account for the telomerase inhibition caused by
9-HE treatment. However, it is not clear how these protein
kinases and protein phosphatase are involved in controlling
telomerase activity in cancer cells. Further investigation of the
molecular relation between telomerase and protein kinases
should provide a new anticancer strategy.
We conclude that 9-HE may exert a potent inhibitory e¡ect
on telomerase activity in cultured pancreatic cancer cells,
probably through inhibition of protein kinases, although the
precise molecular mechanism of telomerase inhibition remains
to be elucidated.
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